Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03975829CT.gov Pediatric Long-Term Follow-up and Rollover Study | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neurofibromatosis Type 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trametinib (this asset) | Novartis Pharmaceuticals | Approved | B · 61 |
| Dabrafenib | Novartis Pharmaceuticals | P4 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Rituximab | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Melphalan | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells | Masonic Cancer Center, University of Minnesota | P2 | CCC |
+6 more in the Neurofibromatosis Type 1 cohort
Other indications for Trametinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P4 | BB · 69 |
| Anaplastic Pleomorphic Xanthoastrocytoma | — | P4 | BB · 69 |
| Anaplastic Oligodendroglioma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DabrafenibNovartis PharmaceuticalsB
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitMasonic Cancer Center, University of MinnesotaCCC
- FludarabineMasonic Cancer Center, University of MinnesotaCCC
- RituximabMasonic Cancer Center, University of MinnesotaCCC
- BusulfanumMasonic Cancer Center, University of MinnesotaCCC
Citation
Floatz Terminal. Trametinib in Neurofibromatosis Type 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trametinib-neurofibromatosis-type-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →